Torrent Pharma Q1 Results FY2023, PAT at Rs. 354 crores

Torrent Pharma Q1 Results FY2023

Corporate Action
by Shreya Anaokar Last Updated: 2022-08-01T18:30:18+05:30

On 29th July 2022, Torrent Pharma announced its quarterly results for the first quarter of FY2023.

Q1FY23 Key Highlights:

- The company reported its Revenue at Rs. 2,347 crores up by 10%.  

- The Gross margins were at 72% and EBITDA margins at 32%. 

- EBITDA stood at Rs. 742 crores and was up by 3%.  

- Net profit after tax at Rs. 354 crores was up by 7%. 


Geographical Highlights:


- Indian market revenues were at Rs. 1,245 crores grew by 14%.

-  As per secondary market data (AIOCD), Torrent’s Q1 FY23 growth was 17% versus IPM growth of 2%

-  Strong outperformance of top brands together with new launches continued to drive market share gains across focus therapies.

-  During the quarter, Torrent added 300 MRs bringing the total field force strength to 4,200



- Brazil's revenue at Rs 184 crores, up by 20%.

- Constant currency revenue at R$ 117 million was up by 8%.

- Adjusted for the discontinued tender business in the previous year, the growth is 10%.

-  As per secondary market data, Torrent’s Q1 growth of 10% was in line with market growth. 

- Growth was aided by strong growth in the generic segment, the performance of top brands, and new launches.


United States:

- US revenue at Rs 299 crores, up by 13%. 

- Constant currency revenue at $39 million was up by 7%.

- Revenue was complemented by the performance of Dapsone launched in the previous quarter. 

- As of June 30, 2022, 60 ANDAs were pending approval with USFDA, and 3 tentative approvals were received. During the quarter, 1 ANDAs was filed. 



- Germany's revenue stood at Rs 214 crores, down by 18%. 

- Constant currency revenue were Euro 26 million. 

- Growth was adversely impacted due increase in competition and loss of tenders in previous quarters. 

- Torrent has already initiated measures to improve price competitiveness. 


Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Shreya Anaokar is a Content Writer at 5paisa. She has completed her Master’s in Finance and Graduation in Statistics from the University of Mumbai. 


Investment/Trading is subject to market risk, past performance doesn’t guarantee future performance. The risk of trading/investment loss in securities markets can be substantial. Also, the above report is compiled from data available on public platforms.

Open Free Demat Account

& get benefits worth 2100*

Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code
Account belongs to

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number